Epithalon
Cell and animal studies. Human work comes largely from one research group and lacks modern controlled trials.
At a glance. A small synthetic peptide from the Russian bioregulator research tradition, studied for its effect on telomerase.
Written and maintained by the AVERON Research Desk · Last reviewed September 2026
What it is
Epithalon, also spelled Epitalon, is a synthetic peptide of just four amino acids: alanine, glutamic acid, aspartic acid and glycine, often abbreviated AEDG. It was developed at the St Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson, as a synthetic version of the active component of Epithalamin, an extract of the pineal gland.
It belongs to a group the Russian researchers call peptide bioregulators: very short peptides proposed to influence gene activity in specific tissues.
What researchers study it for
Ageing and longevity, telomere length, circadian rhythm and melatonin regulation, and tumour development in ageing animals.
What the research shows
The finding most often cited was published by Khavinson and colleagues in the Bulletin of Experimental Biology and Medicine in 2003. In human cells grown in the laboratory, Epithalon activated telomerase, the enzyme that rebuilds telomeres, and lengthened the telomeres of those cells.
In animal studies, including work by Vladimir Anisimov and colleagues published in Biogerontology in 2003, Epithalon was reported to slow some markers of ageing, extend lifespan in certain mouse strains and reduce the incidence of some spontaneous tumours.
Human studies exist but come mostly from the same research tradition, were small, and were not conducted to the standard of modern randomised controlled trials.
What it does not do, and what is not known
- No independent, controlled human trial has shown that Epithalon lengthens telomeres in people or extends human lifespan.
- Lengthening telomeres in cells grown in a dish is not the same as slowing ageing in a person.
- Most of the research comes from one group, and it has not been widely replicated elsewhere.
- Telomerase activation carries a theoretical concern: cancer cells also rely on telomerase. This has not been shown to be a problem in practice, but it is a genuine reason for caution.
- Any effect on ageing would not be something that can be felt or measured by the user.
Adverse effects reported in research
The published studies report it as well tolerated, but there is no systematic, independent human safety data and no long-term data.
Regulatory and anti-doping status
Regulatory: Not approved as a medicine anywhere.
Anti-doping: With no approval for human therapeutic use, it falls under WADA's category S0 (non-approved substances). Prohibited at all times in tested sport.
At AVERON
Supplied as research-grade material, Epithalon 10 mg. A 50 mg vial is planned.
Independent lab report: 79789_HGDSATZ3PURY
Frequently asked questions
Doses mentioned on this page are the arms of published studies or the terms of an approved product, given to describe the evidence. They are not guidance.
Sources
- Khavinson VKh, Bondarev IE, Butyugov AA.. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 2003;135(6):590–592. Link
- Anisimov VN, Khavinson VKh, Popovich IG, et al.. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003;4:193–202. Link
- World Anti-Doping Agency. The Prohibited List. WADA. Link

